Detalles de la búsqueda
1.
A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).
Jpn J Clin Oncol;
54(1): 103-107, 2024 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37801434
2.
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
Br J Cancer;
128(8): 1603-1608, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36782009
3.
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Br J Cancer;
128(10): 1897-1905, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871043
4.
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Int J Clin Oncol;
27(4): 684-694, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35089459
5.
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Int J Clin Oncol;
25(4): 614-621, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838590
6.
[Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer].
Gan To Kagaku Ryoho;
47(11): 1577-1581, 2020 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-33268731
7.
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Cancer Sci;
110(11): 3565-3572, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31520559
8.
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
Cancer Sci;
110(3): 1032-1043, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30657223
9.
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Oncologist;
23(1): 7-15, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28894015
10.
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Gastric Cancer;
21(5): 792-801, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29353332
11.
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Lancet Oncol;
18(9): 1172-1181, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28760399
12.
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Target Oncol;
19(1): 59-69, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194163
13.
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Sci Rep;
13(1): 17931, 2023 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37863951
14.
Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
Cancers (Basel);
15(21)2023 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37958346
15.
Prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer.
J Gastrointest Oncol;
14(6): 2384-2394, 2023 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38196526
16.
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
Target Oncol;
18(3): 369-381, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148491
17.
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study.
J Gastrointest Oncol;
13(6): 2769-2778, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36636083
18.
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Intern Med;
61(15): 2255-2261, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35908959
19.
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric Cancer.
JCO Precis Oncol;
6: e2200135, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35952320
20.
NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
J Cancer Res Clin Oncol;
148(10): 2841-2854, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35622165